Drug Information Update- Public Meeting on Functional GI Disorders Patient-Focused Drug Development

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

On May 11, 2015, FDA will conduct a public meeting on Functional GI Disorders Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of functional GI disorders on daily life and patients’ views on currently available therapies to treat the functional GI disorders, such as irritable bowel syndrome, gastroparesis, chronic persistent symptomatic gastroesophageal reflux despite standard therapeutic interventions, and chronic idiopathic constipation.

Date: May 11, 2015

Time: 1:00 p.m. to 5:00 p.m.

Location:

FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
Enter at Building 1 to clear security
(Information about arrival to FDA's White Oak campus)

Registration:

To register for this meeting, visit: Register online

Registration will close on May 1, 2015.

Submitting comments to the public docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 13, 2015.

• FDA is interested in patient responses to the questions listed in the Federal Register Notice.
• Visit the Public Docket to submit your comment

You may also find this information on FDA's webpage: Public Meeting on Functional GI Disorders Patient-Focused Drug Development.

---

This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.

• For additional drug information, please visit the DDI Web page.
• For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter:FDA_Drug_Info.
• This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).